Form 4 for COGT Cogent Biosciences, Inc.
Accepted 2025-01-15 00:00:00 ET · period of report 2025-01-14 · accession 0000950170-25-005630 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-15 | 2025-01-14 | COGT | Pinnow Cole | Chief Commercial Off | P - Purchase | $7.60 | +43.8K | 45.8K | +2,085% | +$332.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-14 | P | A | 43,750 | $7.60 | 45,848 | D | — | — | (F1) The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $7.53 to $7.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. (F2) Includes an aggregate of 1,398 shares acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on December 31, 2024. |